If you search for a HER2-targeted therapy near you, Herceptin (trastuzumab) will come up as a 5-star option. The only problem is, there’s no other generic choices for those days you just can’t swing 4 dollar-signs. But those days are soon to be over. A double-blinded phase 3 trial reported last week in JCO demonstrates that the trastuzumab biosimilar SB3 is non-inferior to Herceptin in the neoadjuvant setting for HER2(+) breast cancer. It’s already entered the EU market as Ontruzant, but we're willing to bet 6.4 billion dollars that Roche won't give up its market exclusivity rights in the US without a fight.


Popular Posts